No one should have to read during the holidays. That’s why we made you a video!
I spoke to our own James Peyer about how he got started in the longevity world, the unique challenges of bringing new anti-aging therapeutics to the public, and how his role as an investor allows him to help projects move through the pipeline.
Tegan McCaslin
Tegan is Geroscience's lead editor, and writes on a variety of topics--mainly science, medicine, and humans--here and elsewhere on the web.
